Today: 19 May 2026
Browse Category

Pfizer 1 November 2025 - 22 December 2025

Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer on Dec. 22 announced a new metastatic prostate cancer research program with Flagship Pioneering and Repertoire Immune Medicines, the eighth under their alliance. The move follows Pfizer’s Dec. 16 guidance projecting flat-to-down 2026 revenue, ongoing COVID product declines, and increased R&D spending. Management warned of “bumpy” years ahead as exclusivity losses weigh on sales.
22 December 2025
····
Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer shares traded near $25.19 as of Dec. 20, 2025, following the company’s 2026 guidance projecting $59.5–$62.5 billion in revenue and adjusted EPS of $2.80–$3.00. The stock saw heavy volume after management cited lower COVID sales, patent expiries, and deal dilution as headwinds. U.S. drug-pricing deals and new Medicare pilot programs added pressure.
21 December 2025
····
Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer shares closed Thursday at $25.04 and held near that level in after-hours trading as investors weighed the company’s 2026 outlook and ongoing U.S. drug pricing policy changes. Pfizer forecast 2026 revenue between $59.5 billion and $62.5 billion, and adjusted EPS of $2.80 to $3.00. The company expects COVID-19 product sales to drop to about $5 billion in 2026.
19 December 2025
··
Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer shares fell nearly 5% to about $25 in U.S. trading Tuesday after the company issued 2026 guidance with adjusted EPS of $2.80–$3.00, below Wall Street estimates. The stock reversed early gains as investors reacted to lower COVID-19 sales and patent expirations expected to pressure results next year. Trading volume topped 55 million shares by late morning.
16 December 2025
····
Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer shares closed Monday at $26.43, up 2.24%, then slipped to $26.34 after hours. Investors are awaiting Tuesday’s analyst call, where management is set to outline 2026 guidance. The company announced a new autoimmune research deal with Adaptive Biotechnologies, worth up to $890 million in milestones. Trading volume was about 60 million shares, below average.
16 December 2025
···
Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025

Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025

Pfizer shares traded near $26.36 on December 15, 2025, close to their 52-week high, with a market cap around $150 billion. The company announced new immunology research agreements with Adaptive Biotechnologies worth up to $890 million. Investors are awaiting Pfizer’s full-year 2026 guidance call scheduled for December 16. Dividend yield stands at about 6.5%, with analyst consensus broadly Hold.
15 December 2025
··
Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer shares traded at $25.85 as of 12:08 UTC Monday, unchanged from Friday’s close. The company will hold a conference call Tuesday morning to provide full-year 2026 financial guidance. Pfizer’s board declared a $0.43 first-quarter 2026 dividend, marking its 349th consecutive quarterly payout. Market cap stands near $147 billion.
15 December 2025
····
Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025)

Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025)

Pfizer shares closed at $25.85, below their 52-week high but above the low. The company declared a $0.43 first-quarter 2026 dividend, its 349th consecutive payout. Investors await Tuesday’s analyst call, where management will issue full-year 2026 guidance. A new obesity drug licensing deal with YaoPharma was also announced.
14 December 2025
··
Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer shares closed down 1.7% at $25.33 on December 9, 2025, with volume below average. After hours, the stock edged up to $25.40 as investors reacted to Pfizer’s new global licensing deal with YaoPharma for an early-stage oral obesity drug. The agreement includes a $150 million upfront payment and potential milestones up to $2.1 billion.
10 December 2025
····
Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer shares closed at $25.74 on November 28, 2025, down 1.8% over the past year. Regulatory filings show new institutional buying, and the company completed a Metsera acquisition worth up to $10 billion. Pfizer reduced its BioNTech stake by 54.7% and raised its full-year EPS guidance to $3.00–$3.15 after reporting $16.7 billion in Q3 revenue.
30 November 2025
····
Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer shares rose 2.62% to close at $25.04 Friday after the FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer and positive data emerged for its mRNA flu vaccine. Volume reached 73 million shares. The stock outperformed Johnson & Johnson and Eli Lilly but remains about 10% below its 52-week high. Pfizer is still down for the year and trades well below pandemic-era peaks.
22 November 2025
··
Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Pfizer shares surged 15% in late September after announcing a Medicaid drug price deal with the Trump administration, but fell back to $24.65 by Oct. 31. The company will report Q3 2025 earnings on Nov. 4, with analysts expecting a year-over-year drop in profit. Pfizer agreed to buy obesity drug developer Metsera for up to $7.3 billion as it seeks new growth beyond COVID-19 products.
1 November 2025
··
1 2

Stock Market Today

  • Polymarket Teams with Nasdaq Private Market to Launch Private Company Prediction Contracts
    May 19, 2026, 4:47 PM EDT. Polymarket has launched a new category of prediction markets for private companies in collaboration with Nasdaq Private Market, enabling trading on pre-IPO company events like funding rounds and valuations. This innovation aims to boost price discovery in typically opaque private markets. Polymarket's move targets the growing number of unicorns-startups valued over $1 billion-with nearly 1,600 globally. The partnership signals increasing institutional interest in prediction markets tied to private equity amid improving regulatory support and market infrastructure. Despite this, retail investors currently drive 80% of prediction market volume, according to a recent Bitget Wallet and Polymarket report. This development could enhance transparency and forecasting in private capital markets, drawing more professional engagement.

Latest articles

Google Stock Slips as Alphabet’s $5 Billion AI Cloud Bet Faces Wall Street’s New Test

Google Stock Slips as Alphabet’s $5 Billion AI Cloud Bet Faces Wall Street’s New Test

19 May 2026
Alphabet Class A shares fell 2.3% to $387.66 Tuesday after Google announced new Gemini AI models, paid subscription tiers, and a $5 billion Blackstone-backed AI cloud venture. The stock had traded as high as $401.71 intraday. Google also cut prices on its top AI subscription plans and introduced Gemini 3.5 Flash, but the stronger 3.5 Pro model remains unreleased.
Nvidia Earnings Date Locked In as Wall Street Awaits AI Stock Moves

Nvidia Earnings Date Locked In as Wall Street Awaits AI Stock Moves

19 May 2026
Nvidia will report fiscal first-quarter earnings after markets close Wednesday, with analysts expecting revenue near $79 billion, up almost 80% from a year ago. Options traders are pricing a 6.5% one-day move in Nvidia shares, or about $355 billion in market value. Shares closed Tuesday at $220.61, valuing the company at $5.4 trillion. Investors are watching for guidance on AI data center spending and competition in AI chips.
NextNRG shares double as buying spikes, but the numbers show a catch

NextNRG shares double as buying spikes, but the numbers show a catch

19 May 2026
NextNRG shares more than doubled Tuesday, closing at $0.8288 and rising to about $0.91 after hours, after reporting April revenue up 56% to $9.4 million, its highest on record. Gross margin for April reached 8.3%. Trading volume topped 344 million shares, with market value near $135 million. The company posted a first-quarter net loss of $10.8 million and had $208,048 in cash at March 31.
Go toTop